MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
41.10
-0.21
-0.51%
After Hours: 41.45 +0.35 +0.85% 16:16 07/13 EDT
OPEN
40.25
PREV CLOSE
41.31
HIGH
41.62
LOW
39.72
VOLUME
570.33K
TURNOVER
--
52 WEEK HIGH
47.84
52 WEEK LOW
4.390
MARKET CAP
2.57B
P/E (TTM)
-9.8467
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KOD last week (0706-0710)?
Weekly Report · 17h ago
Weekly Report: what happened at KOD last week (0629-0703)?
Weekly Report · 07/06 10:05
Kodiak Sciences: Buy Rating Reiterated as KSI-101’s MESI Opportunity Supports Maintained $65 Price Target
TipRanks · 06/29 17:05
Weekly Report: what happened at KOD last week (0622-0626)?
Weekly Report · 06/29 10:01
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
Benzinga · 06/26 14:18
Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth
NASDAQ · 06/25 07:45
10 mid-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 06/24 13:45
Weekly Report: what happened at KOD last week (0615-0619)?
Weekly Report · 06/22 10:09
More
About KOD
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.